US2010021439A1PendingUtilityA1

Methods and compositions for treating intervertebral disc degeneration

63
Assignee: MOEHLENBRUCK JEFFREY WILLIAMPriority: Apr 7, 2000Filed: Jun 2, 2009Published: Jan 28, 2010
Est. expiryApr 7, 2020(expired)· nominal 20-yr term from priority
Inventors:Jeffrey William MoehlenbruckJohn Ranieri
A61P 43/00A61L 27/3895A61F 2002/444A61L 27/3817A61L 27/3856A61L 27/3683A61L 2430/38A61L 27/3612A61P 19/00A61L 27/3687A61L 27/3658A61L 27/50A61L 27/3834A61L 2400/06A61P 19/08
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A fluid matrix comprising cross-linked remodelable collagen from a donor vertebrate animal is useful for regenerating hydrodynamic function in damaged intervertebral discs in vivo. The matrix may be injectable and may comprise cells and a plurality of purified cell growth factors. The matrix promotes cell growth and elaboration of proteoglycans to facilitate regeneration of native tissues. The collagen in the matrix may be cross-linked using photooxidative catalysis and visible light, and purified cell growth factors are preferably at least partly bone-derived.

Claims

exact text as granted — not AI-modified
1 - 59 . (canceled) 
     
     
         60 . A composition for augmenting nucleus pulposus comprising, a cell enhancement agent, a blood component and a polymerizable or cross-linkable viscosity control agent. 
     
     
         61 . The composition of  claim 60  wherein the cell enhancement agent comprises a proteoglycan. 
     
     
         62 . The composition of  claim 61  wherein the proteoglycan has been modified by the addition of a cross-linkable moiety. 
     
     
         63 . The composition of  claim 60  wherein the cell enhancement agent comprises hyaluronic acid. 
     
     
         64 . The composition of  claim 63  wherein the hyaluronic acid comprises human recombinant hyaluronic acid. 
     
     
         65 . The composition of  claim 63  wherein the hyaluronic acid comprises hyaluronic acid derived from a donor nucleus pulposus. 
     
     
         66 . The composition of  claim 60  wherein the viscosity control agent comprises a polymer. 
     
     
         67 . The composition of  claim 66  wherein the polymer comprises a polyalkylene glycol. 
     
     
         68 . The composition of  claim 67  wherein the polyalkylene glycol comprises functionalized polyalkylene glycol. 
     
     
         69 . The composition of  claim 60  wherein the blood component comprises a natural blood component. 
     
     
         70 . The composition of  claim 60  wherein the blood component comprises serum. 
     
     
         71 . The composition of  claim 60  wherein the blood component comprises a human blood component. 
     
     
         72 . The composition of  claim 60  wherein the viscosity control agent is polymerizable or cross-linkable in situ. 
     
     
         73 . The composition of  claim 72  comprising a viscosity control agent is polymerizable or cross-linkable by exposure to light. 
     
     
         74 . The composition of  claim 72  wherein the viscosity control agent comprises a water soluble macromonomer. 
     
     
         75 . The composition of  claim 72  wherein the viscosity control agent comprises hyaluronic acid, polyalkylene glycol, chitosan or fibrin. 
     
     
         76 . The composition of  claim 72  wherein the viscosity control agent comprises a proteoglycan. 
     
     
         77 . The composition of  claim 72  wherein at least a portion of the viscosity control agent is functionalized with at least a first polymerizable or cross-linkable moiety selected from the group consisting of glycidyl methacrylate, methacrylate anhydride, and methacroyl chloride. 
     
     
         78 . The composition of  claim 60  wherein the composition further comprises a growth factor. 
     
     
         79 . The composition of  claim 60  wherein the composition has a viscosity sufficient for delivery to an intervertebral disc via a cannula. 
     
     
         80 . The composition of  claim 60  wherein the composition is capable of being delivered to a patient as a low viscosity liquid and gelled in situ to a higher viscosity liquid or semi-solid. 
     
     
         81 . The composition of  claim 60  wherein the composition further comprises steroidal or non-steroidal anti-inflammatory drugs, anesthetics, antibiotics, or combinations thereof. 
     
     
         82 . The composition of  claim 60  wherein the composition further comprises cells. 
     
     
         83 . The composition of  claim 60  wherein the composition further comprises an active agent.

Join the waitlist — get patent alerts

Track US2010021439A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.